Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Genetic anticipation and cardiac conduction abnormalities in myotonic dystrophy type 1, implications for early stratification from a multicenter registry

  • Lorca Gutiérrez, Rebeca
  • Moliner-Abós, Carles|||0000-0002-9264-5804
  • Alen, Alberto
  • De Frutos, Fernando|||0000-0003-4350-3217
  • Peña-Peña, María Luisa
  • Villacorta, Eduardo|||0000-0003-0486-1740
  • Ripoll-Vera, Tomás|||0000-0001-9222-325X
  • Zorio, Esther|||0000-0003-3608-4210
  • Larrañaga-Moreira, José M.|||0000-0002-8370-5158
  • García-Pavía, Pablo|||0000-0002-5470-2257
  • García-Hernández, Soledad|||0000-0003-2547-685X
  • Palomino-Doza, Julián
  • Soriano-Amores, Marc|||0000-0002-6000-1828
  • Muñoz-Batet, Carmen|||0000-0002-4150-8834
  • Báez-Ferrer, Néstor
  • Martínez-Gimeno, Aaron
  • Bermúdez-Jiménez, José
  • Limeres, Javier
  • Tiron, Coloma
  • Cabrera-Romero, Eva
  • Espinosa, María Angeles
  • Piqueras-Flores, Jesús
  • Morís, Germán|||0000-0001-7608-2194
  • Carrillo-Mora, Lidia María
  • Syris, Petros
  • Alvarez-Velasco, Rut
  • Gimeno-Blanes, Juan Ramón
DM1 is an autosomal dominant disorder caused by unstable CTG repeats that expand over lifetime and in successive generations, contributing to genetic anticipation. Cardiac conduction abnormalities (CCAs) are a major source of morbidity and premature death in DM1, yet the influence of age at diagnosis, generation, and CTG repeat length on the timing and progression of cardiac involvement remains poorly defined. This multicentric retrospective study included 549 adult DM1 patients from 16 hospitals in Spain. The primary composite endpoint comprised significant CCAs, device implantation, malignant ventricular arrhythmias and cardiac syncope. Patients were stratified by age-at-diagnosis (.
Repisalud
Publication Artículo científico (JournalArticle)

Proteomic analysis of plasma proteins of high-flux haemodialysis and on-line haemodiafiltration patients reveals differences in transthyretin levels related with anaemia.

  • Martinez-Alonso, Emma
  • Alcazar, Paula
  • Camafeita, Emilio
  • Fernandez-Lucas, Milagros
  • Ruiz-Roso, Gloria
  • Alcazar, Alberto
A large proportion of end-stage renal disease (ESRD) patients under long-term haemodialysis, have persistent anaemia and require high doses of recombinant human erythropoietin (rhEPO). However, the underlying mechanisms of renal anaemia have not been fully elucidated in these patients. In this study, we will be focusing on anaemia and plasma proteins in ESRD patients on high-flux haemodialysis (HF) and on-line haemodiafiltration (HDF), to investigate using two proteomic approaches if patients undergoing these treatments develop differences in their plasma protein composition and how this could be related to their anaemia. The demographic and biochemical data revealed that HDF patients had lower anaemia and much lower rhEPO requirements than HF patients. Regarding their plasma proteomes, HDF patients had increased levels of a protein highly similar to serotransferrin, trypsin-1 and immunoglobulin heavy constant chain alpha-1, and lower levels of alpha-1 antitrypsin, transthyretin, apolipoproteins E and C-III, and haptoglobin-related protein. Lower transthyretin levels in HDF patients were further confirmed by transthyretin-peptide quantification and western blot detection. Since ESRD patients have increased transthyretin, a protein that can aggregate and inhibit transferrin endocytosis and erythropoiesis, our finding that HDF patients have lower transthyretin and lower anaemia suggests that the decrease in transthyretin plasma levels would allow an increase in transferrin endocytosis, contributing to erythropoiesis. Thus, transthyretin could be a critical actor for anaemia in ESRD patients and a novel player for haemodialysis adequacy.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Nonlinear propagation and control of acoustic waves in phononic superlattices

  • Jimenez, Noe|||0000-0002-6539-670X
  • Picó Vila, Rubén|||0000-0003-3537-9658
  • García-Raffi, L. M.|||0000-0003-3985-8453
  • Sánchez Morcillo, Víctor José|||0000-0003-4766-1263
  • Mehrem, Ahmed
The propagation of intense acoustic waves in a one-dimensional phononic crystal is studied. The medium consists in a structured fluid, formed by a periodic array of fluid layers with alternating linear acoustic properties and quadratic nonlinearity coefficient. The spacing between layers is of the order of the wavelength, therefore Bragg effects such as band gaps appear. We show that the interplay between strong dispersion and nonlinearity leads to new scenarios of wave propagation. The classical waveform distortion process typical of intense acoustic waves in homogeneous media can be strongly altered when nonlinearly generated harmonics lie inside or close to band gaps. This allows the possibility of engineer a medium in order to get a particular waveform. Examples of this include the design of media with effective (e.g., cubic) nonlinearities, or extremely linear media (where distortion can be canceled). The presented ideas open a way towards the control of acoustic wave propagation in nonlinear regime., Work supported by Spanish Ministry of Economy and Innovation and European Union FEDER through projects FIS2011-29731-C02-02 and MTM2012-36740-C02-02. AM and LMGR acknowledge Generalitat Valenciana under grants Santiago Grisolia program (grant 2012/029) and BEST2015/279 respectively. RP and VJSM acknowledge the Spanish Ministry of Economy and Innovation under grants CAS14/00232 and PRX14/00705 respectively.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Epigenetic study of cohort of monozygotic twins with hypertrophic cardiomyopathy due to MYBPC3 (Cardiac Myosin-Binding Protein C)

  • Peñarroya, Alfonso
  • Lorca, Rebeca
  • Rodríguez Reguero, José Julián
  • Gómez, Juan
  • Avanzas, Pablo
  • Tejedor, Juan Ramón
  • Fernández, Agustín F.
  • Fraga, Mario F.
[Background]: Hypertrophic cardiomyopathy is an autosomal dominant cardiac disease. The mechanisms that determine its variable expressivity are poorly understood. Epigenetics could play a crucial role in bridging the gap between genotype and phenotype by orchestrating the interplay between the environment and the genome regulation. In this study we aimed to establish a possible correlation between the peripheral blood DNA methylation patterns and left ventricular hypertrophy severity in patients with hypertrophic cardiomyopathy, evaluating the potential impact of lifestyle variables and providing a biological context to the observed changes., [Methods and results]: Methylation data were obtained from peripheral blood samples (Infinium MethylationEPIC BeadChip arrays). We employed multiple pair-matched models to extract genomic positions whose methylation correlates with the degree of left ventricular hypertrophy in 3 monozygotic twin pairs carrying the same founder pathogenic variant (MYBPC3 p.Gly263Ter). This model enables the isolation of the environmental influence, beyond age, on DNA methylation changes by removing the genetic background. Our results revealed a more anxious personality among more severely affected individuals. We identified 56 differentially methylated positions that exhibited moderate, proportional changes in methylation associated with left ventricular hypertrophy. These differentially methylated positions were enriched in regions regulated by repressor histone marks and tended to cluster at genes involved in left ventricular hypertrophy development, such as HOXA5, TRPC3, UCN3, or PLSCR2, suggesting that changes in peripheral blood may reflect myocardial alterations., [Conclusions]: We present a unique pair-matched model, based on 3 monozygotic twin pairs carrying the same founder pathogenic variant and different phenotypes. This study provides further evidence of the pivotal role of epigenetics in hypertrophic cardiomyopathy variable expressivity., This work was supported by Health Institute Carlos III cofunding El Fondo Europeo de Desarrollo Regional- FEDER (PI22/00705 to J.G. and R.L.; PI18/01527 and PI21/01067 to M.M.F. and A.F.F.; COV00624 to J.R.T. and M.M.F.), the Spanish Association Against Cancer (PROYE18061FERN to M.M.F.), the Asturias Government (PCTI) cofunding 2018- 2023/FEDER (IDI/2018/146 and IDI/2021/000077 to M.M.F.), and the European Commission NextGenerationEU, through Consejo Superior de Investigaciones Científicas’s Global Health Platform (PTI Salud Global), and the Spanish Ministry of Science and Innovation through the Recovery, Transformation and Resilience Plan (SGL2021- 03- 39 and SGL2021- 03- 040). A.P. is supported by the Health Institute Carlos III (FI19/00085)., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Validation of semaphorin 7A and ala-β-his-dipeptidase as biomarkers associated with the conversion from clinically isolated syndrome to multiple sclerosis

  • Cantó Puig, Ester|||0000-0002-8149-0296
  • Tintoré, Mar|||0000-0001-9999-5359
  • Villar, Luisa M.|||0000-0002-9067-3668
  • Borràs, Eva|||0000-0002-3859-9907
  • Alvarez-Cermeño, José C.|||0000-0002-1345-2837
  • Chiva, Cristina
  • Sabidó, Eduard|||0000-0001-6506-7714
  • Rovira, Alex|||0000-0002-2132-6750
  • Montalban, Xavier|||0000-0002-0098-9918
  • Comabella López, Manuel|||0000-0002-2373-6657
In a previous proteomics study using pooled cerebrospinal fluid (CSF) samples, we proposed apolipoprotein AI, apolipoprotein AIV, vitronectin, plasminogen, semaphorin 7A, and ala-β-his-dipeptidase as candidate biomarkers associated with the conversion to clinically definite multiple sclerosis (CDMS) in patients with clinically isolated syndromes (CIS). Here, we aimed to validate these results in individual CSF samples using alternative techniques. In a first replication study, levels of apolipoproteins AI and AIV, vitronectin, and plasminogen were measured by ELISA in CSF and serum of 56 CIS patients (29 patients who converted to CDMS (MS converters) and 27 patients who remained with CIS during follow-up (MS non-converters)) and 26 controls with other neurological disorders. Semaphorin 7A and ala-β-his-dipeptidase levels were determined by selected reaction monitoring (SRM) in CSF of 36 patients (18 MS converters, 18 non-converters) and 20 controls. In a second replication study, apolipoprotein AI levels were measured by ELISA in CSF of 74 CIS patients (47 MS converters, 27 non-converters) and 50 individual controls, and levels of semaphorin 7A and ala-beta-his-dipeptidase were determined by SRM in 49 patients (24 MS converters, 25 non-converters) and 22 controls. CSF levels of apolipoprotein AI were increased (P = 0.043) and levels of semaphorin 7A and ala-β-his-dipeptidase decreased (P = 4.4 × 10 -10 and P = 0.033 respectively) in MS converters compared to non-converters. No significant differences were found in serum levels for apolipoproteins AI and AIV, vitronectin, and plasminogen. Findings with semaphorin 7A and ala-β-his-dipeptidase were also validated in the second replication study, and CSF levels for these two proteins were again decreased in MS converters versus non-converters (P = 1.2 × 10 -4 for semaphorin 7A; P = 3.7 × 10 -8 for ala-β-his-dipeptidase). Conversely, apolipoprotein AI findings were not replicated and CSF levels for this protein did not significantly differ between groups. Furthermore, CSF semaphorin 7A levels were negatively associated with the number of T2 lesions at baseline and one-year follow-up. These results validate previous findings for semaphorin 7A and ala-β-his-dipeptidase, and suggest that these proteins play a role as CSF biomarkers associated with the conversion to CDMS in CIS patients. The online version of this article (doi:10.1186/s12974-014-0181-8) contains supplementary material, which is available to authorized users.